At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy
In Brief
A Phase 4 clinical trial evaluating Bevacizumab, Vitrectomy, and 1 other intervention for Proliferative Diabetic Retinopathy and 2 related conditions. Completed, enrolled 69 participants across 1 site.
Detailed Summary
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is useful. In the present prospective, double-masked, randomized, controlled study, we aimed to verify the usefulness of intravitreal injection of 0.16 mg/0.05 ml bevacizumab one day before conducting vitrectomy for PDR.
Study Details
Timeline
Interventions
0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
vitrectomy of 25 gauge system.
Sham injection one day before vitrectomy